tradingkey.logo

Penumbra Inc

PEN
341.020USD
-0.990-0.29%
Close 02/06, 16:00ETQuotes delayed by 15 min
13.35BMarket Cap
80.66P/E TTM

Penumbra Inc

341.020
-0.990-0.29%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Penumbra Inc

Currency: USD Updated: 2026-02-06

Key Insights

Penumbra Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 357.05.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Penumbra Inc's Score

Industry at a Glance

Industry Ranking
30 / 205
Overall Ranking
116 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Penumbra Inc Highlights

StrengthsRisks
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.02% year-on-year.
Undervalued
The company’s latest PE is 80.66, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 38.52M shares, decreasing 2.96% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 171.00 shares of this stock.

Analyst Rating

Based on 19 analysts
Hold
Current Rating
357.053
Target Price
+4.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Penumbra Inc is 8.95, ranking 23 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 354.69M, representing a year-over-year increase of 17.82%, while its net profit experienced a year-over-year increase of 55.28%.

Score

Industry at a Glance

Previous score
8.95
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.38

Operational Efficiency

9.31

Growth Potential

9.51

Shareholder Returns

7.54

Penumbra Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Penumbra Inc is 3.84, ranking 200 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 80.66, which is 2393.72% below the recent high of 2011.41 and 6611.13% above the recent low of -5251.80.

Score

Industry at a Glance

Previous score
3.84
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 30/205
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Penumbra Inc is 6.74, ranking 161 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 320.00, with a high of 355.00 and a low of 266.00.

Score

Industry at a Glance

Previous score
6.74
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 19 analysts
Hold
Current Rating
357.053
Target Price
+4.40%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

114
Total
6
Median
9
Average
Company name
Ratings
Analysts
Penumbra Inc
PEN
19
Stryker Corp
SYK
32
Medtronic PLC
MDT
31
Dexcom Inc
DXCM
31
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Penumbra Inc is 9.10, ranking 17 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 372.29 and the support level at 299.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.15
Change
-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-6.424
Neutral
RSI(14)
51.879
Neutral
STOCH(KDJ)(9,3,3)
9.715
Oversold
ATR(14)
4.556
Low Volatility
CCI(14)
-161.663
Sell
Williams %R
92.678
Oversold
TRIX(12,20)
0.490
Sell
StochRSI(14)
4.127
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
347.188
Sell
MA10
352.854
Sell
MA20
345.851
Sell
MA50
322.287
Buy
MA100
289.681
Buy
MA200
275.601
Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Penumbra Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 98.19%, representing a quarter-over-quarter increase of 3.59%. The largest institutional shareholder is The Vanguard, holding a total of 3.76M shares, representing 9.59% of shares outstanding, with 1.26% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
5.10M
+1.16%
The Vanguard Group, Inc.
Star Investors
3.83M
-0.66%
BlackRock Institutional Trust Company, N.A.
3.58M
-0.69%
T. Rowe Price Associates, Inc.
Star Investors
1.76M
+31.17%
State Street Investment Management (US)
1.16M
-0.49%
Elsesser (Adam)
1.02M
+1.21%
Citadel Advisors LLC
971.00K
+343.39%
Wellington Management Company, LLP
832.91K
-2.83%
Baillie Gifford & Co.
Star Investors
908.55K
-1.47%
RTW Investments L.P.
866.50K
+0.34%
1
2

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Penumbra Inc is 7.74, ranking 31 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Penumbra Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Score

Industry at a Glance

Previous score
7.74
Change
0
Beta vs S&P 500 index
0.81
VaR
+3.85%
240-Day Maximum Drawdown
+24.76%
240-Day Volatility
+42.56%

Return

Best Daily Return
60 days
+11.82%
120 days
+17.32%
5 years
+17.32%
Worst Daily Return
60 days
-5.79%
120 days
-5.79%
5 years
-10.03%
Sharpe Ratio
60 days
+2.93
120 days
+1.66
5 years
+0.27

Risk Assessment

Maximum Drawdown
240 days
+24.76%
3 years
+52.44%
5 years
+62.56%
Return-to-Drawdown Ratio
240 days
+0.75
3 years
+0.15
5 years
+0.03
Skewness
240 days
+2.24
3 years
+1.15
5 years
+0.88

Volatility

Realised Volatility
240 days
+42.56%
5 years
+43.33%
Standardised True Range
240 days
+2.59%
5 years
+2.46%
Downside Risk-Adjusted Return
120 days
+327.03%
240 days
+327.03%
Maximum Daily Upside Volatility
60 days
+31.16%
Maximum Daily Downside Volatility
60 days
+32.99%

Liquidity

Average Turnover Rate
60 days
+1.19%
120 days
+1.28%
5 years
--
Turnover Deviation
20 days
+2.27%
60 days
+8.96%
120 days
+16.98%

Peer Comparison

Healthcare Equipment & Supplies
Penumbra Inc
Penumbra Inc
PEN
7.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
Becton Dickinson and Co
BDX
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
Align Technology Inc
ALGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI